Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

The highest value deals in March were again dominated by company acquisitions but only one mega merger, Abbvie's acquisition of Pharmacyclics.

The price of $21bn was regarded by many commentators as very high and there were accusations that Abbvie had overpaid - but the reason for this was not the share price premium. [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.

Licensor/Licensee Acquired / Acquirer
Deal type*
Product/Technology
Headline $m
Pharmacyclics / Abbvie
Company acquisition
Marketed BTK inhibitor for haematological cancers + pipeline incl. 3 products in clinic
21,000
Auspex / Teva
Company acquisition
Phase 3 product for Huntington's Chorea + deuterium technology platform
3,500
Ikaria / Mallinckrodt
Company acquisition
Marketed critical care treatments incl. respiratory for neonatals
2,300
Cordis (J&J) / Cardinal Health
Company acquisition
J&J divest subsidiary marketing vascular devices
1,944
Covis / Concordia
Asset acquisition
18 marketed brands and generics in US acquired by Canadian company
1,200
Hyperion / Horizon
Company acquisition
2 marketed urea cycle disorder orphan drugs in the US
1,100
Bavarian Nordic / BMS
Option to license and commercialise
Phase 3 immuno-oncology treatment for prostate cancer
975
Intrexon / Merck Serono
Licence and collaboration + option
CAR-T immuno-oncology platform for identifying and developing target molecules
941
AstraZeneca / Daiichi Sankyo
Co-commercialisation US 
Marketed Movantik (naloxegol) for opioid induced constipation
825
Aduro / Novartis
Licence and collaboration
Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway
750
Hanmi / Eli Lilly
Licence and collaboration**
Phase 1 BTK inhibitor for treatment of lupus
690
Innovent / Eli Lilly
Strategic alliance
Development and commercialisation with Chinese company 3 preclinical oncology drugs†
456+
Zogenix / Pernix
Acquisition product
US marketed hydrocodone (Zohydro ER) for treatment of pain
384
Cellular Dynamics / Fujiflim
Company acquisition
US-based developer and manufacturer of human cells
307
Blueprint / Alexion
Strategic collaboration China and rest of world
Kinase inhibitor platform for discovery of molecules for treatment of rare diseases
265
Immunogen / Takeda
Licence and collaboration + option
Antibody-drug conjugate (ADC) technology to develop 2 anticancer products + option on 3rd
230
SuppreMol / Baxter
Company acquisition
Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus
225
Athersys / Chugai
Licence and collaboration Japan
Phase 2 stem cell therapy for treatment of ischaemic stroke
205
Alkermes / Recro
Asset acquisition
Purchase of US factory and associated products and pipeline
170
Checkpoint Therapeutics / TG
Licence and collaboration
Human anti-PD-L1 and anti-GITR antibody preclinical programmes for  haematological cancers
165
Brighthaven Ventures/ Islet Sciences
Licence and collaboration***
Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes
117
Sorrento / Nantcell
Licence and collaboration
Discovery and development of anticancer products incl. CAR-T and checkpoint inhibitors PD-1 and PD-L1
110
Transtech / Calithera
Licence and collaboration
Portfolio of hexokinase II inhibitors for treatment of cancer
109
Astellas / Vical
Licence and collaboration
Preclinical antifungal ASP2397
100

* Licence and collaboration means exclusive global rights to develop and commercialise unless otherwise stated

** Global rights excluding China, Hong Kong, Taiwan and Korea

*** Global rights excluding Latin America, China, Korea, Taiwan and Japan

† Innovent to receive a total upfront payment of $56m and potential milestones of over $400m for one of the molecules, a preclinical immuno-oncology molecule. 

The Deal Watch table is compiled by Medius Associates

13th May 2015

The Deal Watch table is compiled by Medius Associates

13th May 2015

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Infographics